denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: educational grants from Genentech, a member of the Roche Group, Sanofi Genzyme Corporation and Takeda Pharmaceutical Company Ltd. Provided by Clinical Care Options, LLC
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Bleeding Disorders, Hemophilia, Biological, antibodies, Adult, Diseases, Bleeding and Clotting, Therapies, Elderly, red blood cells, Pediatric, Biological Processes, gene therapy, Technology and Procedures, Young Adult, Cell Lineage, gene editing, Study Population, hematopoiesis
Hematology Disease Topics & Pathways:
Bleeding Disorders, Hemophilia, Biological, antibodies, Adult, Diseases, Bleeding and Clotting, Therapies, Elderly, red blood cells, Pediatric, Biological Processes, gene therapy, Technology and Procedures, Young Adult, Cell Lineage, gene editing, Study Population, hematopoiesis
Friday, December 4, 2020: 3:00 PM-6:00 PM
Chair:
Miguel A. Escobar, M.D., University of Texas Health Science Center
Disclosures:
Escobar: Genentech, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; National Hemophilia Foundation: Consultancy, Membership on an entity's Board of Directors or advisory committees; Biomarin, Genetech/Roche, CSL Behring, Kedrion, Magellan Healthcare: Honoraria; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novo Nordisk: Consultancy, Membership on an entity's Board of Directors or advisory committees.
Speakers:
Michael U. Callaghan, MD, Central Michigan University
and
Rebecca Kruse-Jarres, MD, MPH, University of Washington
Disclosures:
Callaghan: Biomarin: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Site Investigator/sub-I Clinical Trial, Speakers Bureau; Global Blood Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Speakers Bureau; Roche/Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Site Investigator/sub-I Clinical Trial, Speakers Bureau; NovoNordisk: Other, Speakers Bureau; Spark: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Site Investigator/sub-I Clinical Trial, Research Funding; Bioverativ: Membership on an entity's Board of Directors or advisory committees; Hema Biologics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sancillio: Other; Alnylum: Current equity holder in publicly-traded company; Grifols: Honoraria, Membership on an entity's Board of Directors or advisory committees; Octapharma: Honoraria, Membership on an entity's Board of Directors or advisory committees. Kruse-Jarres: NovoNordisk: Other; CSLBehring and Genentech/Roche: Research Funding; Biomarin, Chugai, CSLBehring, and Genentech/Roche: Consultancy.
During this webinar, learners will be provided with an overview of current individualized therapeutic approaches to manage patients with hemophilia A and a look ahead at new data and promising agents that may soon change practice. Renowned hemophilia experts will discuss the evidence behind current best practice management strategies for patients with hemophilia A, both with and without inhibitors, requiring prophylaxis. The program will include patient case challenges and reflection on considerations that affect therapeutic decisions. Recent clinical trial data and ongoing trials will be discussed, including emerging extended half-life (EHL) clotting factors, humanized bispecific antibody therapy, and novel therapeutic approaches with antithrombin inhibitors, anti-TFPI antibodies, and gene therapy. Learners will come away with an understanding of how these agents will affect management strategies for patients with hemophilia A in the current clinic and in the near future. Throughout the webinar, attendees will interact with experts through interactive case challenges and polling questions, as well as submitting questions directly to the panel for their consideration.
See more of: Satellite Symposia